SOPHiA GENETICS Statistics
Total Valuation
SOPHiA GENETICS has a market cap or net worth of $704.86 million. The enterprise value is $659.02 million.
| Market Cap | 704.86M |
| Enterprise Value | 659.02M |
Important Dates
The last earnings date was Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SOPHiA GENETICS has 85.13 million shares outstanding. The number of shares has increased by 4.40% in one year.
| Current Share Class | 85.13M |
| Shares Outstanding | 85.13M |
| Shares Change (YoY) | +4.40% |
| Shares Change (QoQ) | +3.80% |
| Owned by Insiders (%) | 8.61% |
| Owned by Institutions (%) | 47.26% |
| Float | 65.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.18 |
| Forward PS | 6.67 |
| PB Ratio | 8.48 |
| P/TBV Ratio | 15.01 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.74.
| Current Ratio | 2.69 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.13 |
Financial Efficiency
Return on equity (ROE) is -101.22% and return on invested capital (ROIC) is -32.29%.
| Return on Equity (ROE) | -101.22% |
| Return on Assets (ROA) | -24.52% |
| Return on Invested Capital (ROIC) | -32.29% |
| Return on Capital Employed (ROCE) | -50.07% |
| Weighted Average Cost of Capital (WACC) | 9.24% |
| Revenue Per Employee | $207,631 |
| Profits Per Employee | -$194,887 |
| Employee Count | 415 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 4.32 |
Taxes
In the past 12 months, SOPHiA GENETICS has paid $578,000 in taxes.
| Income Tax | 578,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +137.25% in the last 52 weeks. The beta is 0.92, so SOPHiA GENETICS's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +137.25% |
| 50-Day Moving Average | 6.04 |
| 200-Day Moving Average | 5.14 |
| Relative Strength Index (RSI) | 74.30 |
| Average Volume (20 Days) | 454,092 |
Short Selling Information
The latest short interest is 768,289, so 0.90% of the outstanding shares have been sold short.
| Short Interest | 768,289 |
| Short Previous Month | 661,352 |
| Short % of Shares Out | 0.90% |
| Short % of Float | 1.18% |
| Short Ratio (days to cover) | 2.34 |
Income Statement
In the last 12 months, SOPHiA GENETICS had revenue of $86.17 million and -$80.88 million in losses. Loss per share was -$1.16.
| Revenue | 86.17M |
| Gross Profit | 57.41M |
| Operating Income | -73.74M |
| Pretax Income | -80.30M |
| Net Income | -80.88M |
| EBITDA | -71.75M |
| EBIT | -73.74M |
| Loss Per Share | -$1.16 |
Balance Sheet
The company has $107.67 million in cash and $61.83 million in debt, with a net cash position of $45.84 million or $0.54 per share.
| Cash & Cash Equivalents | 107.67M |
| Total Debt | 61.83M |
| Net Cash | 45.84M |
| Net Cash Per Share | $0.54 |
| Equity (Book Value) | 83.12M |
| Book Value Per Share | 0.98 |
| Working Capital | 86.21M |
Cash Flow
In the last 12 months, operating cash flow was -$39.74 million and capital expenditures -$1.47 million, giving a free cash flow of -$41.21 million.
| Operating Cash Flow | -39.74M |
| Capital Expenditures | -1.47M |
| Depreciation & Amortization | 2.00M |
| Net Borrowing | -2.18M |
| Free Cash Flow | -41.21M |
| FCF Per Share | -$0.48 |
Margins
Gross margin is 66.63%, with operating and profit margins of -85.58% and -93.86%.
| Gross Margin | 66.63% |
| Operating Margin | -85.58% |
| Pretax Margin | -93.19% |
| Profit Margin | -93.86% |
| EBITDA Margin | -83.26% |
| EBIT Margin | -85.58% |
| FCF Margin | n/a |
Dividends & Yields
SOPHiA GENETICS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.40% |
| Shareholder Yield | -4.40% |
| Earnings Yield | -11.47% |
| FCF Yield | -5.85% |
Analyst Forecast
The average price target for SOPHiA GENETICS is $9.75, which is 17.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 17.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 24.15% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SOPHiA GENETICS has an Altman Z-Score of -2.61 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.61 |
| Piotroski F-Score | 2 |